Source: Eur Respir J 2012; 40: 485-494
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Yamaya Mutsuo, Azuma Arata, Takizawa Hajime, Kadota Jun-ichi, Tamaoki Jun, Kudoh Shoji. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012; 40: 485-494

Member's Comments

No comment yet.

Related content which might interest you: The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease Source: International Congress 2017 – COPD management Year: 2017 Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease Source: Eur Respir J , 49 (3) 1601328; DOI: 10.1183/13993003.01328-2016 Year: 2017 Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – COPD diagnosis and management Year: 2016 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma Source: Annual Congress 2005 - Mechanisms of resolution of inflammation Year: 2005 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 IL-33 blockade impacts mediators of persistence and exacerbation of chronic airway inflammation. Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Beyond corticosteroids: future prospects in the management of inflammation in COPD Source: Eur Respir Rev 2011; 20: 175-182 Year: 2011 Effects of dexamethasone and anti-inflammatory drugs on inflammatory cytokines from bronchial epithelial cells of COPD patients Source: International Congress 2015 – New insights into lung disease pathogenesis Year: 2015 New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD Source: Annual Congress 2005 - Protease-antiprotease revisited Year: 2005 Mucin 1 downregulation associates with corticoid resistance in chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Enhanced cytokine response to exercise in COPD Source: Annual Congress 2006 - COPD and systemic inflammation Year: 2006 The influence of statin supplementation on inflammatory markers in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 325-331 Year: 2002 Interleukin-18 production and pulmonary function in COPD Source: Eur Respir J 2008; 31: 287-297 Year: 2008 Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Why short-term antibiotic use in AECB may influence long-term outcomes Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005